MTOR as a multifunctional therapeutic target in HIV infection

Drug Discovery Today

Volumn 16, Issue 15-16, 2011, Pages 715-721

  Nicoletti, Ferdinando ^a   Fagone, Paolo ^a   Meroni, Pierluigi ^b   McCubrey, James ^c   Bendtzen, Klaus ^d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

^d Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; ENFUVIRTIDE; EVEROLIMUS; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P110; PROTEIN P85; RAPAMYCIN; RAS PROTEIN; RIDAFOROLIMUS; S6 KINASE; TEMSIROLIMUS; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ANUS CANCER; APOPTOSIS; AUTISM; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CANCER RISK; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL LOSS; CHRONIC KIDNEY DISEASE; DEMENTIA; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE FUNCTION TEST; INNATE IMMUNITY; KAPOSI SARCOMA; KIDNEY DISEASE; KIDNEY FAILURE; LUNG CANCER; LYMPHOMA; NEOPLASM; NEPHRITIS; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; REVIEW; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; AUTOPHAGY; CD4-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; TOR SERINE-THREONINE KINASES;

EID: 80051665056     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.05.008     Document Type: Review

References (60)

1. S. Wullschleger TOR signaling in growth and metabolism Cell 124 2006 471 484 (Pubitemid 43199434)
2. R. Zoncu mTOR: from growth signal integration to cancer, diabetes and ageing Nat. Rev. Mol. Cell Biol. 12 2011 21 35
3. S. Sengupta Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress Mol. Cell 2010 310 322
4. K. Düvel Activation of a metabolic gene regulatory network downstream of mTOR complex 1 Mol. Cell 39 2010 171 183
5. D.D. Sarbassov Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr. Biol. 14 2004 1296 1302
6. C. Vézina Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J. Antibiot. (Tokyo) 28 1975 721 726
7. C.M. Hartford, and M.J. Ratain Rapamycin: something old, something new, sometimes borrowed and now renewed Clin. Pharmacol. Ther. 82 2007 381 388 (Pubitemid 47414349)
8. C. Malagelada Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease J. Neurosci. 30 2010 1166 1175
9. D. Ehninger, and A.J. Silva Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders Trends Mol. Med. 17 2011 78 87
10. J.B. Easton, and P.J. Houghton mTOR and cancer therapy Oncogene 25 2006 6436 6446 (Pubitemid 44582287)
11. D.D. Sarbassov Growing roles for the mTOR pathway Curr. Opin. Cell Biol. 17 2005 596 603 (Pubitemid 41540408)
12. M. Donia Potential use of rapamycin in HIV infection Br. J. Clin. Pharmacol. 70 2010 784 793
13. F. Nicoletti Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin Clin. Exp. Immunol. 155 2009 28 34
14. F. Di Benedetto First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation Transplantation 89 2010 733 738
15. K.C. Williams, and T.H. Burdo HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis APMIS 117 2009 400 412
16. Y. Wu, and A. Yoder Chemokine coreceptor signaling in HIV-1 infection and pathogenesis PLoS Pathog. 5 2009 e1000520
17. M. Cadogan, and A.G. Dalgleish HIV immunopathogenesis and strategies for intervention Lancet Infect. Dis. 8 2008 675 684
18. T.H. Mogensen Innate immune recognition and activation during HIV infection Retrovirology 7 2010 54
19. Z. Grossman Pathogenesis of HIV infection: what the virus spares is as important as what it destroys Nat. Med. 12 2006 289 295 (Pubitemid 43355074)
20. S.M. Hammer Antiretroviral treatment of adult HIV infection: recommendations of the International AIDS Society-USA panel JAMA 300 2008 555 570
21. F.J. Palella Jr. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N. Engl. J. Med. 338 1998 853 860 (Pubitemid 28135961)
22. + recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases J. Acquir. Immune Defic. Syndr. 48 2008 541 546
23. + counts greater than 200 cells/mm3 J. Acquir. Immune Defic. Syndr. 44 2007 179 187 (Pubitemid 46292221)
24. J.L. Perfettini Mechanisms of apoptosis induction by the HIV-1 envelope Cell Death Differ. 12 Suppl. 1 2005 916 923
25. M. Castedo Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12- rapamycin-associated protein-mediated p53 phosphorylation J. Exp. Med. 194 2001 1097 1110 (Pubitemid 32995780)
26. L. Espert Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4 J. Clin. Invest. 116 2006 2161 2172 (Pubitemid 44162325)
27. D. Zhou, and S.A. Spector Human immunodeficiency virus type-1 infection inhibits autophagy AIDS 22 2008 695 699 (Pubitemid 351450637)
28. S.A. Spector, and D. Zhou Autophagy: an overlooked mechanism of HIV-1 pathogenesis and neuroAIDS? Autophagy 4 2008 704 706
29. K. Kedzierska Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy J. Clin. Virol. 26 2003 247 263 (Pubitemid 36206609)
30. J. Van Grol HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3 PLoS ONE 5 2010 e11733
31. C. Jagannath Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells Nat. Med. 15 2009 267 276
32. F.P. Blanchet Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses Immunity 32 2010 654 669
33. J.C. McArthur Human immunodeficiency virus-associated neurocognitive disorders: mind the gap Ann. Neurol. 67 2010 699 714
34. S. Simioni Cognitive dysfunction in HIV patients despite long-standing suppression of viremia AIDS 24 2010 1243 1250
35. K. Kibayashi Neuropathology of human immunodeficiency virus infection at different disease stages Hum. Pathol. 27 1996 637 642 (Pubitemid 26240313)
36. M. Alirezaei Decreased neuronal autophagy in HIV dementia: a mechanism of indirect neurotoxicity Autophagy 4 2008 963 966
37. M. Alirezaei Disruption of neuronal autophagy by infected microglia results in neurodegeneration PLoS ONE 3 2008 e2906
38. R. Nardacci Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis Am. J. Pathol. 167 2005 695 704 (Pubitemid 41216355)
39. M.G. Atta Diagnosis and natural history of HIV-associated nephropathy Adv. Chronic Kidney Dis. 17 2010 52 58
40. L. Kaufman The pathogenesis of HIV-associated nephropathy Adv. Chronic Kidney Dis. 17 2010 36 43
41. C.M. Wyatt HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy Semin. Nephrol. 28 2008 513 522
42. D. Kumar HIV-associated nephropathy: role of mammalian target of rapamycin pathway Am. J. Pathol. 177 2010 813 821
43. C. Wood, and W. Harrington Jr. AIDS and associated malignancies Cell Res. 15 2005 947 952 (Pubitemid 41826264)
44. G.M. Clifford, and S. Franceschi Cancer risk in HIV-infected persons: influence of CD4(+) count Fut. Oncol. 5 2009 669 678
45. G. Barbaro, and G. Barbarini HIV infection and cancer in the era of highly active antiretroviral therapy Oncol. Rep. 17 2007 1121 1126
46. M. Guiguet Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Lancet Oncol. 10 2009 1152 1159
47. W. Cáceres AIDS-related malignancies: revisited P. R. Health Sci. J. 29 2010 70 75
48. M.J. Silverberg, and D.I. Abrams Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr. Opin. HIV AIDS 4 2009 42 51
49. M.K. Stelzer Rapamycin inhibits anal carcinogenesis in two preclinical animal models Cancer Prev. Res. (Phila.) 3 2010 1542 1551
50. F. Martellotta AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies Curr. HIV Res. 7 2009 634 638
51. S. Montaner Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma Cell Cycle 6 2007 438 443 (Pubitemid 46393447)
52. G. Stallone Sirolimus for Kaposi's sarcoma in renal-transplant recipients N. Engl. J. Med. 352 2005 1317 1323 (Pubitemid 40411498)
53. A. Carbone AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment Pathology 33 2002 392 404 (Pubitemid 34627589)
54. R. Yarchoan Therapy insight: AIDS-related malignancies - the influence of antiviral therapy on pathogenesis and management Nat. Clin. Pract. Oncol. 2 2005 406 415 (Pubitemid 43115009)
55. M. El-Salem Activation of mTORC1 signaling pathway in AIDS-related lymphomas Am. J. Pathol. 175 2009 817 824
56. L. Leseux Syk-dependent mTOR activation in follicular lymphoma cells Blood 108 2006 4156 4162 (Pubitemid 44913287)
57. M. Majewski Immunosuppressive signal transduction inhibitor RAD suppresses growth of cells derived from post-transplant lymphoproliferative disorder at allograft protecting doses Transplantation 75 2003 1710 1717 (Pubitemid 36629155)
58. M. Boratynska, and D. Smolska Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders Transpl. Int. 21 2008 605 608 (Pubitemid 351600070)
59. A.P. Bhatt Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 2010 4455 4463
60. G. Hess Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J. Clin. Oncol. 27 2009 3822 3829